Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Department of Radiology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA; Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Eur J Surg Oncol. 2014 Jul;40(7):850-8. doi: 10.1016/j.ejso.2014.02.225. Epub 2014 Feb 22.
Despite recent developments in preoperative breast cancer imaging, intraoperative localization of tumor tissue can be challenging, resulting in tumor-positive resection margins during breast conserving surgery. Based on certain physicochemical similarities between Technetium((99m)Tc)-sestamibi (MIBI), an SPECT radiodiagnostic with a sensitivity of 83-90% to detect breast cancer preoperatively, and the near-infrared (NIR) fluorophore Methylene Blue (MB), we hypothesized that MB might detect breast cancer intraoperatively using NIR fluorescence imaging.
Twenty-four patients with breast cancer, planned for surgical resection, were included. Patients were divided in 2 administration groups, which differed with respect to the timing of MB administration. N = 12 patients per group were administered 1.0 mg/kg MB intravenously either immediately or 3 h before surgery. The mini-FLARE imaging system was used to identify the NIR fluorescent signal during surgery and on post-resected specimens transferred to the pathology department. Results were confirmed by NIR fluorescence microscopy.
20/24 (83%) of breast tumors (carcinoma in N = 21 and ductal carcinoma in situ in N = 3) were identified in the resected specimen using NIR fluorescence imaging. Patients with non-detectable tumors were significantly older. No significant relation to receptor status or tumor grade was seen. Overall tumor-to-background ratio (TBR) was 2.4 ± 0.8. There was no significant difference between TBR and background signal between administration groups. In 2/4 patients with positive resection margins, breast cancer tissue identified in the wound bed during surgery would have changed surgical management. Histology confirmed the concordance of fluorescence signal and tumor tissue.
This feasibility study demonstrated an overall breast cancer identification rate using MB of 83%, with real-time intraoperative guidance having the potential to alter patient management.
尽管术前乳腺癌成像技术最近有了发展,但肿瘤组织的术中定位仍然具有挑战性,这导致保乳手术时肿瘤阳性切缘。基于锝(99m)-甲氧基异丁基异腈(MIBI)与近红外(NIR)荧光染料亚甲蓝(MB)之间某些物理化学相似性,我们假设 MB 可能通过近红外荧光成像术在术中检测乳腺癌。
共纳入 24 例计划接受手术切除的乳腺癌患者。患者分为 2 个给药组,给药时间不同。每组 n = 12 例患者,分别于手术前即刻或 3 小时静脉内给予 1.0mg/kg MB。使用 mini-FLARE 成像系统在手术期间和转移至病理科的切除标本上识别近红外荧光信号。结果通过近红外荧光显微镜确认。
24 例乳腺癌(浸润性癌 n = 21 例,导管原位癌 n = 3 例)中,20 例(83%)在切除标本中通过近红外荧光成像识别。未检测到肿瘤的患者年龄明显较大。未发现与受体状态或肿瘤分级有显著关系。总体肿瘤与背景比值(TBR)为 2.4 ± 0.8。两组之间 TBR 和背景信号之间无显著差异。在 4 例阳性切缘患者中,手术过程中在伤口床上识别到的乳腺癌组织可能会改变手术管理。组织学证实了荧光信号与肿瘤组织的一致性。
这项可行性研究表明,MB 总体乳腺癌识别率为 83%,实时术中指导有可能改变患者管理。